134 related articles for article (PubMed ID: 3332191)
1. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M
Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
[TBL] [Abstract][Full Text] [Related]
2. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
Skórski T; Kawalec M
Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
[TBL] [Abstract][Full Text] [Related]
3. Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice.
Skorski T; Kawalec M; Kawiak J
Bone Marrow Transplant; 1990 Jan; 5(1):23-7. PubMed ID: 2297588
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M; Hoser G; Ratajczak M; Gnatowski B; Kawiak J
Bone Marrow Transplant; 1988 Nov; 3(6):543-51. PubMed ID: 2905613
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune resistance against L1210 lymphatic leukemia in mice after lethal irradiation and reconstruction with fetal liver cells.
Skórski T; Ratajczak MZ; Kawalec M; Kawiak J
Folia Histochem Cytobiol; 1991; 29(3):121-4. PubMed ID: 1794437
[TBL] [Abstract][Full Text] [Related]
6. Early induction of immune resistance against leukemia in mice after lethal irradiation followed by syngeneic bone marrow transplantation and injection of syngeneic leukocytes.
Skórski T; Kawalec M; Kawiak J
Transplantation; 1991 Apr; 51(4):843-7. PubMed ID: 2014540
[TBL] [Abstract][Full Text] [Related]
7. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
8. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation.
Karussis DM; Slavin S; Lehmann D; Mizrachi-Koll R; Abramsky O; Ben-Nun A
J Immunol; 1992 Mar; 148(6):1693-8. PubMed ID: 1541813
[TBL] [Abstract][Full Text] [Related]
9. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
10. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
Jiang R; Bony V; Lopez M
Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
[No Abstract] [Full Text] [Related]
13. Major histocompatibility complex class II expression is required for posttransplant immunological but not hemopoietic reconstitution in mice.
Huss R; Beckham C; Storb R; Deeg HJ
Transplantation; 1994 Dec; 58(12):1366-71. PubMed ID: 7809930
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the ability to purge tumor from murine bone marrow using clonogenic assays.
Jones RJ; Colvin OM; Sensenbrenner LL
Cancer Res; 1988 Jun; 48(12):3394-7. PubMed ID: 3285994
[TBL] [Abstract][Full Text] [Related]
15. Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1).
Loewenthal E; Weiss L; Samuel S; Or R; Slavin S
Bone Marrow Transplant; 1993 Aug; 12(2):109-13. PubMed ID: 8401354
[TBL] [Abstract][Full Text] [Related]
16. Leukemia inhibitory factor induces in vivo expansion of bone marrow progenitor cells that accelerate hematopoietic reconstitution but do not enhance radioprotection in lethally irradiated mice.
Pruijt JF; Lindley IJ; Heemskerk DP; Willemze R; Fibbe WE
Stem Cells; 1997; 15(1):50-5. PubMed ID: 9007222
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic and nondividing mafosfamide-treated L 1210 cells--comparison of lines resistant and nonresistant to cyclophosphamide.
Kawalec M; Hoser G; Skórski T; Kawiak J
Folia Histochem Cytobiol; 1993; 31(2):63-6. PubMed ID: 8405569
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of benzoporphyrin derivative, a photosensitizer, in selective destruction of leukemia cells using a murine tumor model.
Jamieson C; Richter A; Levy JG
Exp Hematol; 1993 May; 21(5):629-34. PubMed ID: 8513863
[TBL] [Abstract][Full Text] [Related]
19. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
